Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab long-term safety in pediatric asthma
NCT03560466Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2018
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of dupilumab in asthma, sponsored by Sanofi. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03560466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03560466.